Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Following the licensure of sanofi pasteur\'s 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated. The present study is part of this endeavor. It is primarily a formulation/dose-finding study with a secondary aim at generating safety and immunogenicity data for the final formulation for the development of a pre-pandemic vaccine.
Epistemonikos ID: 567e73017a8b736aa4ca2216ebb6bd46ff5da066
First added on: May 05, 2024